Heart failure & cardiomyopathiesResearch article
Potential Global Impact of Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure
- Decision analytical modelling study
Authors' conclusion
Optimal implementation of SGLT-2 inhibitors globally in HF is projected to prevent/postpone approximately 7-8 million worsening HF events and cardiovascular deaths over 3 years.
Study context
- Population
- Global heart failure (HF) population eligible for SGLT2 inhibitors (GBD 2017 prevalence, NHANES exclusions, REPORT-HF left ventricular ejection fraction (LVEF) distributions)
- Comparison
- Optimal global implementation of SGLT2 inhibitors in HF
- Outcome
- Worsening HF events and CV deaths prevented/postponed (composite)
- Follow-up
- 3 years
Main finding
As reported in the abstract
Worsening HF events and CV deaths prevented/postponed
- Eligible HF patients, all LVEFs
- 49 329 000 (95% CI 43 882 000-54 929 000)
- Eligible, LVEF ≤40%
- 25 651 000 (95% CI 22 818 000-28 563 000)
- Eligible, LVEF >40%
- 23 678 000 (95% CI 21 063 000-26 366 000)
- Events prevented/postponed, LVEF <40%
- 4 512 011 (95% CI 4 013 686-5 024 232) to 5 986 943 (95% CI 5 325 721-6 666 604)
- Events prevented/postponed, LVEF >40%
- 2 102 606 (95% CI 1 870 394-2 341 301) to 2 557 224 (95% CI 2 274 804-2 847 528)
- Events prevented/postponed, all eligible
- 7 069 235 (95% CI 6 288 490-7 871 760) to 8 089 549 (95% CI 7 196 115-9 007 905)
Original publication
Potential Global Impact of Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure. Eur J Heart Fail. Published 24 April 2023. doi:10.1002/ejhf.2864
Summarised from the published abstract; every number is checked against it